Lysophosphatidylethanolamine improves diastolic dysfunction by alleviating mitochondrial injury in the aging heart

Guiwen Xu, Wei Xiao, Peng Sun, Yuanjun Sun, Xinyu Yang, Xiaomeng Yin, Yang LiuJournal of Lipid Research 2024 · DOI

TL;DR

Aging hearts suffer from diastolic dysfunction linked to mitochondrial problems, particularly a decrease in phosphatidylethanolamine (PE). This study shows that supplementing with lysophosphatidylethanolamine (LPE) in aging mice restores mitochondrial PE levels, improves mitochondrial structure and function, and ultimately alleviates age-related diastolic dysfunction.

What Problem Does This Paper Address?

Heart failure with preserved ejection fraction (HFpEF) is a growing problem, especially in the elderly. Aging itself is a major risk factor for HFpEF, and a key contributor is the decline in cardiac mitochondrial function. This decline is characterized by structural abnormalities, reduced energy production, and increased oxidative stress. While it's known that mitochondrial lipid metabolism is altered in aging cells, the specific role of these lipid changes in mitochondrial dysfunction and HFpEF pathogenesis remains unclear. This paper aims to bridge this gap by investigating whether a specific lipid, phosphatidylethanolamine (PE), is reduced in aging heart mitochondria and if restoring its levels can counteract age-related mitochondrial damage and improve cardiac function.

Methods

The researchers employed a multi-faceted approach to investigate the role of PE and the effects of LPE treatment:

  • Animal Models: Adult (3-month-old) and aged (22-month-old) C57BL/6J mice were used. Aging mice were treated with varying doses of LPE or saline for three months.
  • Echocardiography: This standard technique was used to assess cardiac function, specifically diastolic function (measured by the E/A ratio) and structural parameters like left ventricular wall thickness.
  • Transmission Electron Microscopy (TEM): Used to visualize and quantify mitochondrial morphology, including area, cristae density, perimeter, and Feret's diameter.
  • Mitochondrial Membrane Potential Assessment: JC-1 staining was employed to measure the membrane potential, with a shift from red (high potential) to green (low potential) indicating dysfunction.
  • Reactive Oxygen Species (ROS) Detection: MitoSOX and DCFH-DA assays were used to measure mitochondrial and intracellular ROS, respectively.
  • Lipidomics: Liquid chromatography-mass spectrometry (LC-MS) was used to analyze the lipid composition of cardiac mitochondria, identifying specific lipid subclasses and their relative abundance.
  • Gene Expression Analysis: RNA-sequencing (RNA-seq) and real-time PCR were used to examine the expression of genes involved in mitochondrial dynamics, metabolism, and lipid synthesis pathways.
  • Cell Culture Experiments: AC16 cardiomyocytes were used to study the effects of PISD knockdown (to reduce PE synthesis) and LPE treatment on mitochondrial function.

Datasets

The study utilized data from experiments performed on adult and aged mice. Specific datasets generated include:

  • Echocardiographic data for cardiac function assessment.
  • TEM images for mitochondrial morphology analysis.
  • Fluorescence intensity data from JC-1, MitoSOX, and DCFH-DA assays for mitochondrial membrane potential and ROS levels.
  • Lipidomic profiles of cardiac mitochondria.
  • RNA-seq data for gene expression analysis.
  • Quantitative data from cell culture experiments.

The paper also refers to supplemental data (Supplemental Tables S1-S3 and Supplemental Figs. S1-S3) which likely contain detailed lists of genes, primers, and experimental results.

Key Insights and Ideas

  • PE is a critical player in aging cardiac mitochondria: The significant decrease in PE in aging heart mitochondria is a key finding, suggesting a direct link between this lipid deficiency and mitochondrial dysfunction.
  • LPE supplementation is a viable therapeutic strategy: The study demonstrates that exogenous LPE can effectively increase mitochondrial PE levels and, more importantly, reverse age-related mitochondrial damage and improve cardiac function. This opens a potential therapeutic avenue for age-related cardiac issues.
  • Mitochondrial structure and function are tightly linked to lipid composition: The findings highlight how alterations in mitochondrial lipids, specifically PE, directly impact mitochondrial morphology (cristae, size) and function (respiration, membrane potential, ROS production).
  • Targeting lipid metabolism can influence mitochondrial dynamics: The observed changes in the expression of genes related to mitochondrial fusion and fission (e.g., OPA1, MFN2, DRP1) after LPE treatment suggest that restoring PE levels can influence the dynamic balance of mitochondria.

Key Results

  • Diastolic Dysfunction in Aging Mice: 50% of aging mice exhibited diastolic dysfunction (E/A < 1), with a 42.2% reduction in the E/A ratio compared to adult mice.
  • Mitochondrial PE Reduction: Aging mouse cardiac mitochondria showed significantly decreased PE levels.
  • LPE Treatment Restores PE: LPE supplementation (at 200 µg/kg) significantly increased PE content in aging mouse hearts.
  • Improved Mitochondrial Morphology and Function: LPE treatment in aging mice led to improved mitochondrial surface area, cristae density, perimeter, and Feret's diameter. It also increased mitochondrial membrane potential and decreased mitochondrial and intracellular ROS.
  • Alleviation of Diastolic Dysfunction: LPE treatment significantly improved diastolic function in aging mice, as evidenced by increased E/A ratios and reduced incidence of E/A < 1.
  • Reduced Cardiac Hypertrophy and Fibrosis: LPE treatment markedly ameliorated age-induced cardiac hypertrophy and fibrosis.
  • Gene Expression Modulation: LPE treatment positively influenced the expression of genes involved in mitochondrial homeostasis and metabolism, including fusion genes (OPA1, MFN1, MFN2) and OXPHOS complex genes.

Limitations and Future Work

  • Dosage and Safety: While the study identified a safe and effective dose of LPE (200 µg/kg), higher doses (400 and 800 µg/kg) showed significant mortality in mice, indicating a need for careful dose regulation.
  • Mechanism of LPE Action: While the study shows LPE improves PE levels and mitochondrial function, the precise molecular mechanisms by which LPE itself is transported and utilized to restore PE synthesis or function require further investigation.
  • Long-term Effects: The study focused on a 3-month treatment period. Long-term effects and potential side effects of LPE supplementation in aging individuals are not yet known.
  • Translational Potential: While promising in mice, further research is needed to confirm these findings in human studies and to develop LPE as a therapeutic agent for HFpEF.
  • Broader Lipidome Impact: The study focused on PE, but aging hearts exhibit broader lipidomic changes. Further research could explore the interplay of other altered lipids and their combined impact on mitochondrial health.

Summary updated

Abstract

Diastolic dysfunction in aging mice is linked to mitochondrial abnormalities, including mitochondrial morphology disorders and decreases in membrane potential. Studies also show that aberrant mitochondrial lipid metabolism impairs mitochondrial function in aging cardiomyocytes. Our lipidomic analysis revealed that phosphatidylethanolamine (PE) levels were significantly decreased in aging myocardial mitochondria. Here, we investigated whether a reduction in PE levels in myocardial mitochondria contributes to mitochondrial injury as well as HFpEF pathogenesis and whether modulation of PE levels could ameliorate aging-induced HFpEF. Echocardiography was used to assess cardiac diastolic function in adult and aging mice treated with lysophosphatidylethanolamine (LPE) or saline. Mitochondrial morphologies from tissue samples were evaluated by transmission electron microscopy (TEM), while mitochondrial membrane potential and reactive oxygen species (ROS) levels were assessed using JC-1, MitoSOX, and DCFH-DA detection assays. We performed GO enrichment analysis between adult and aging mice and discovered significant enrichment in transcriptional programs associated with mitochondria and lipid metabolism. Also, mitochondrial PE levels were significantly decreased in aging cardiomyocytes. Treatment with LPE (200 μg/kg) significantly enhanced PE content in aging mice and improved the structure of mitochondria in cardiac cells. Also, LPE treatment protects against aging-induced deterioration of mitochondrial injury, as evidenced by increased mitochondrial membrane potential and decreased mitochondrial ROS. Furthermore, treatment with LPE alleviated severe diastolic dysfunction in aging mice. Taken together, our results suggest that LPE treatment enhances PE levels in mitochondria and ameliorates aging-induced diastolic dysfunction in mice through a mechanism involving improved mitochondrial structure and function.
BibTeX
@article{xu2024lysophosphatidylethanolamine,
  author = {Guiwen Xu and Wei Xiao and Peng Sun and Yuanjun Sun and Xinyu Yang and Xiaomeng Yin and Yang Liu},
  title = {{Lysophosphatidylethanolamine improves diastolic dysfunction by alleviating mitochondrial injury in the aging heart}},
  journal = {Journal of Lipid Research},
  year = {2024},
  doi = {10.1016/j.jlr.2024.100713},
}
Figure